Tags: Renal Cell Carcinoma
Choosing the Best Approach for Patients With Favorable-Risk Metastatic Renal Cell Carcinoma
From the 18th International Kidney Cancer Symposium November 15-16, 2019, Miami, Florida Oncologists treating patients with favorable-risk metastatic renal cell carcinoma (RCC) have multiple choices, ranging […]
Evolving Landscape of the Treatment of Metastatic Clear Cell Renal Cell Carcinoma
Abstract: The management of advanced clear cell renal cell carcinoma (RCC) has evolved over the past decade with the introduction of targeted therapies and immune […]
Contemporary Management of Advanced Renal Cell Carcinoma
Abstract: Kidney cancer is the eighth most commonly diagnosed cancer in the United States, and nearly one-third of patients have locally advanced or metastatic disease […]
Hem/Onc News
Rucaparib Approved for Maintenance Treatment in Recurrent Ovarian Cancer On April 6, the US Food and Drug Administration (FDA) approved rucaparib (Rubraca, Clovis Oncology) for maintenance […]
Cost-Effectiveness in the Surgical Care of Renal Cell Carcinoma
From the 16th International Kidney Cancer Symposium November 3-4, 2017, Miami, Florida When it comes to the surgical care of patients with kidney cancer, more is […]
How We Treat Brain Metastases in Metastatic Renal Cell Carcinoma
Overview • Brain metastasis in patients with metastatic renal cell carcinoma generally signifies a poor prognosis. • Surgical resection is an option for patients with […]
Current and Emerging First-Line Systemic Therapies in Clear Cell Renal Cell Carcinoma
H&O Which patients with clear cell renal cell carcinoma (RCC) are candidates for systemic therapy? BR All patients with clear cell RCC are potential candidates […]
Cabozantinib Approved for First-Line Treatment of Advanced Renal Cell Carcinoma
Cabozantinib (Cabometyx, Exelixis) received an expanded indication from the US Food and Drug Administration (FDA) on December 19 as a first-line treatment in patients with advanced […]
Highlights in Kidney Cancer From the 2017 American Society of Clinical Oncology Annual Meeting
1From the 2017 American Society of Clinical Oncology Annual Meeting June 2-6, 2017 • Chicago, Illinois Adjuvant Pazopanib Does Not Extend Disease-Free Survival in Locally Advanced […]
Highlights in Kidney Cancer
Highlights in Kidney Cancer: From the American Society of Clinical Oncology Genitourinary Cancers Symposium February 16-18, 2017 • Orlando, Florida Computer Assistance Reduces Errors in Evaluation […]
Combined Blockade of Vascular Endothelial Growth Factor and Programmed Death 1 Pathways in Advanced Kidney Cancer
Abstract: Targeted and immune-based therapies have improved outcomes in advanced kidney cancer, yet novel strategies are needed to extend the duration of these benefits and […]
The Future of Immunotherapy as Perioperative Therapy in Renal Cell Carcinoma
Reports from the International Kidney Cancer Symposium November 5-6, 2016, Miami, Florida Researchers are launching 2 new studies of checkpoint inhibitors as perioperative treatment for patients with […]
VEGF Inhibitors in Renal Cell Carcinoma
Abstract: The arrival of targeted therapies—vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors—and programmed death 1 (PD-1) inhibitors has […]
Kidney Cancer News
Cancer Vaccine Fails to Improve Survival in Metastatic Renal Cell Carcinoma The addition of the IMA901 multipeptide cancer vaccine to sunitinib (Sutent, Pfizer) did not […]
Adjuvant Treatment for Renal Cell Carcinoma: Do We Finally Have a Major Breakthrough?
Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Devin N. Patel, MD, Robert A. Figlin, MD, and Hyung L. Kim, MD The […]